期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

前蛋白转化酶枯草溶菌素9的生物学功能 被引量：9

Biological Functions on PCSK9
下载PDF
导出
摘要 前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)基因属于前蛋白转化酶(PC)家族,是一个新发现不久的与胆固醇代谢相关基因.近年来,PCSK9在其生物学效应及疾病中的作用越来越受到重视.大量的研究表明,除通过调节低密度脂蛋白受体(LDLR)影响胆固醇代谢外,PCSK9还参与细胞凋亡,促进肝发育、再生,促进神经系统发育,影响神经系统分化并且与炎症过程以及糖尿病相关.本文对PCSK9功能方面最新研究进展进行了综述。 Proprotein convertase subtilisin /kexin type 9（PCSK9） belongs to the proprotein convertase（PC） family and is related to cholesterol metabolism as newly discovered.PCSK9 has been recently attracted increasing attention with regard to its biological effects and role in disease processes.Novel functions have been reported,such as participate in cell apoptosis,promote the development and regeneration of the liver,influence the development or differentiation of the nervous system,and associate with inflammatory processes and diabetes,etc.,besides of the regulation of the low density lipoprotein receptor（LDLR） in cholesterol metabolism.
作者 江璐 龚慧琴 刘录山
机构地区 南华大学心血管疾病研究所动脉硬化学湖南省重点实验室
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2010年第12期1085-1089,共5页 Chinese Journal of Biochemistry and Molecular Biology
基金 国家自然科学基金资助项目(No.30700325) 湖南省应用基础研究计划重点项目(No.2008FJ2006)资助 湖南省高校科技创新团队支持计划资助 湖南省教育厅重点科研项目(No.10A105)~~
关键词 前蛋白转化酶枯草溶菌素9 胆固醇代谢 凋亡 炎症 糖尿病 proprotein convertase subtilisin /kexin type 9（PCSK9） cholesterol metabolism apoptosis inflammation diabetes
分类号 R363 [医药卫生—病理学]
  • 相关文献

参考文献31

  • 1Seidah N G, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 ( NARC-1 ) : liver regeneration and neuronal differentiation [ J ]. Proc Natl Acad Sci U S A,2003,100(3) :928-933.
  • 2Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 [ J ]. J Biol Chem, 2008,283 ( 4 ) : 2363- 2372.
  • 3Grefhorst A, Mcnutt M C, Lagace T A, et al. Plasma PCSK9 preferentially reduces liver LDL receptors in mice [ J ]. J Lipid Res,2008,49 (6) :1303-1311.
  • 4Abifadel M, Rabes J P, Boileau C, et al. After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9 [ J]. Ann Endocrinol (Paris) ,2007, 68(2-3) : 138-146.
  • 5Martin B, Solanas-Barca M, Garcia-Otin A L, et al. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia[ J]. Nutr Metab Cardiovasc Dis, 2010,20(4) :236-242.
  • 6Varret M, Abifadel M, Rabes J P, et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia [ J ]. Clin Genet, 2008,73(1 ) :1-13.
  • 7Lopez D. PCSK9 : an enigmatic protease [ J]. Biochim Biophys Acta, 2008,1781 ( 4 ) : 184-191.
  • 8Lambert G, Charlton F, Rye K A, et al. Molecular basis of PCSK9 function [J]. Atherosclerosis,2009, 203 ( 1 ) : 1-7.
  • 9Homer V M, Marais A D, Charhon F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa[J]. Atherosclerosis,2008,196(2) :659-666.
  • 10Hallman D M, Srinivasan S R, Chen W, et al. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood(from The Bogalusa Heart Study) [ J]. Am J Cardiol,2007, 100( 1 ) : 69-72.

二级参考文献53

  • 1程艳丽,谢闵,刘录山,王贵学.pcsk9基因突变与胆固醇血症[J].中国生物化学与分子生物学报,2007,23(3):172-176. 被引量：6
  • 2Elagoz A, Benjannel S, Mammarbassi A, et al. Biosynthesis and cellular trafficking of the convertase SKI-1/SIP: eetodomain shedding requires SKI-1activity. J Biol Chem, 2002, 277 (13): 11265- 11275
  • 3Seidah N G, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.Proc Natl Acad Sci USA, 2003, 100(3): 928-933
  • 4Maxwell K N, Fisher E A, Breslow J L, et al. Over expression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA, 2005, 102(6): 2069-2074
  • 5Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase PCSK9/NARC-1 in the development of the nervous system. J Neurochem, 2006, 98(3): 838-850
  • 6Peterson A S, Fong L G, Young S G. PCSK9 function and physiology. J Lipid Res, 2008, 49(6): 1152- 1156
  • 7Bingham B, Shen R, Kotnis S, et al. Proapoptotic effects ofNARC 1 (= PCSKg), the gene encoding a novel serine proteinase. Cytometry A, 2006, 69(11): 1123-1131
  • 8Brown M S, Goldstein J L. Lowing LDL-not only how low, but how long?. Science, 2006, 311(5768): 1721 - 1723
  • 9Libby P, Geng Y J, Aikawa M, et al. Macrophage and atherosclerotic plaque stability. Curr Opin Lipidol, 1996, 7(5): 330-335
  • 10Boyle J J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture, Curr Vasc Pharmacol, 2005, 3 (1): 63-68

共引文献25

同被引文献118

  • 1Lynn Htet Aung,YIN Rui-xing,MIAO Lin,HU Xi-jiang, YAN Ting-ting,CAO Xiao-li,WU Dong-feng,LI Qing,PAN Shang-ling,WU Jin-zhen (Department of Cardiology,Institute of Cardiovascular Diseases, The First Affiliated Hospital,Guangxi Medical University, Nanning 530021,China).The proprotein convertase subtilisin/kexin type 9 geneE670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations[J].岭南心血管病杂志,2011,17(S1):162-162. 被引量：9
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量：33022
  • 3JOY T R. Novel therapeutic agents for lowering low density lipo-protein cholesterol [ J ]. Pharmacol Ther, 2012,135(1):31 -43.
  • 4TIBOLLA G, NORATA G Df ARTALI et al. Proprotein con-vertase subtilisin/kexin type 9 ( pcsk9) : from structure - functionrelation to therapeutic inhibition[ J]. Nutr Metab Cardiovasc Dis,2011,21(11) : 835 -843.
  • 5ABIFADEL M, RAB^S J P, DEVILLEHS M, et al. Mutationsand polymorphisms in the proprotein convertase subtilisin kexin 9(PCSK9) gene in cholesterol metabolism and disease[ J]. HumMutat, 2009, 30(4) : 520-529.
  • 6FATTORI E, CAPPELLETTI M, LO SURDO P, et al. Immuniza-tion against proprotein convertase subtilisin ~ like/kexin type 9lowers plasma LDL - cholesterol levels in mice[ J]. J Lipid Res,2012,53(8) : 1654-1661.
  • 7DUFF C J, HOOPER N M. PCSK9 : an emerging target for treat-ment of hypercholesterolemia [ J ]. Expert Opin Ther Targets,2011,15(2) : 157 -168.
  • 8CHEN T J,JI C Y, HU Y H. Genetic and environmental influ-ences on serum lipids and the effects of puberty : a Chinese twinstudy[J]. Acta Paediatr, 2009,98(6) : 1029 -1036.
  • 9CRUNKHORN S. Trial watch: PCSK9 antibody reduces LDL cho-lesterol [J ]. Nat Rev Drug Discov, 2012, 11(1):11.
  • 10Chen TJ, Ji CY, Hu YH. Genetic and environmental influences on serum lipids and the effects of puberty : a Chinese twin study [ J ]. Acta Paediatr, 2009, 98(6) : 1029 - 1036.

引证文献9

二级引证文献48

中国生物化学与分子生物学报
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部